Evidence map›Paper›PMID 31521648›Full record

ReviewJACC. Cardiovascular interventions2019

Procedural Strategies to Reduce the Incidence of Contrast-Induced Acute Kidney Injury During Percutaneous Coronary Intervention.

Marcel Almendarez, Hitinder S Gurm, José Mariani, Matteo Montorfano, Emmanouil S Brilakis, Roxana Mehran, Lorenzo Azzalini

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in JACC. Cardiovascular interventions, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05037695 (SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease), which is not on this map. Cited by 46 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05037695 phase4unknown statusstarted 2021, after this paper: background citation

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)

Ran2021Enrolled40Registered outcomes17Posted comparisons0ConditionsAcute Kidney Injury, Coronary Artery Disease, Diabetes Mellitus, Type 2Armsempagliflozin 25 mg
PMID 30990260PMID 20686453PMID 23895807PMID 24135581PMID 24226524PMID 25271206PMID 25994513PMID 27299675PMID 27391020PMID 28130255PMID 28382626PMID 28437734other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marcel AlmendarezInterventional Cardiology Division, Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy; Interventional Cardiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Hitinder S GurmDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
José MarianiDepartment of Interventional Cardiology, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil; Santa Casa de São Paulo, São Paulo, Brazil. Electronic address: https://twitter.com/mariani_jr.
Matteo MontorfanoInterventional Cardiology Division, Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy.
Emmanouil S BrilakisCenter for Advanced Coronary Interventions, Minneapolis Heart Institute, Minneapolis, Minnesota. Electronic address: https://twitter.com/esbrilakis.
Roxana MehranInterventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: https://twitter.com/Drroxmehran.
Lorenzo AzzaliniInterventional Cardiology Division, Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy. Electronic address: azzalini.lorenzo@hsr.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Contrast-induced acute kidney injury (CI-AKI) is a potentially serious complication following coronary angiography and percutaneous coronary intervention (PCI). The incidence of CI-AKI is particularly high in patients with advanced chronic kidney disease (defined as an estimated glomerular filtration rate <30 ml/min/1.73 m

Indexed as

Acute Kidney InjuryContrast MediaCoronary AngiographyHumansIncidencePercutaneous Coronary InterventionProtective FactorsRadiography, InterventionalRisk AssessmentRisk FactorsTreatment OutcomeContrast Mediachronic kidney diseasecontrast-induced acute kidney injurycontrast-induced nephropathyintravascular ultrasoundoptical coherence tomographypercutaneous coronary intervention

Identifiers

PMID31521648

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.